tradingkey.logo
搜尋

Bausch + Lomb Corp

BLCO
添加自選
16.910USD
-0.090-0.53%
收盤 07-31 16:00美東報價延遲15分鐘
6.04B總市值
虧損本益比TTM

關於 Bausch + Lomb Corp 公司

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

Bausch + Lomb Corp簡介

公司代碼BLCO
公司名稱Bausch + Lomb Corp
上市日期May 06, 2022
CEOSaunders (Brenton L)
員工數量13500
證券類型Ordinary Share
年結日May 06
公司地址520 Applewood Crescent
城市VAUGHAN
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Canada
郵編L4K 4B4
電話19082552864
網址https://ir.bausch.com/
公司代碼BLCO
上市日期May 06, 2022
CEOSaunders (Brenton L)

Bausch + Lomb Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
87.02K
-1.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
72.80K
-18.77%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
87.02K
-1.16%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
72.80K
-18.77%
Karen Ling ,
Karen Ling ,
Independent Director
Independent Director
57.52K
+62.90%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
27.66K
+57.27%
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas W. Ross, Sr.
Mr. Thomas W. Ross, Sr.
Lead Independent Director
Lead Independent Director
--
--

常見問題

Bausch + Lomb Corp的前五大股東是誰?

Bausch + Lomb Corp的前五大股東如下:Mr. Luc Bonnefoy

有多少機構持有Bausch + Lomb Corp(BLCO)的股份?

截至2026Q1,共有249家機構持有Bausch + Lomb Corp的股份,合計持有的股份價值約為40.30M,占公司總股份的11.30% 。與2025Q4相比,機構持股有所增加,增幅為-25007155.00。

哪個業務部門對Bausch + Lomb Corp的收入貢獻最大?

在2026Q1,Devices業務部門對Bausch + Lomb Corp的收入貢獻最大,創收1.92B,占總收入的37.68% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有